Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics
Journal of Pharmacology and Experimental Therapeutics – June 18, 2003
Source: OpenAlex
Summary
Ayahuasca, a traditional Amazonian brew, significantly alters neurotransmitter activity. In a trial with 30 participants, those consuming ayahuasca exhibited a 50% increase in active metabolites like harmine and harmaline, which inhibit monoamine oxidase. This pharmacological action enhances the effects of other compounds in the brew, leading to profound hallucinogenic experiences. In contrast, the placebo group showed no such changes. The findings underscore the complex chemistry behind psychedelics and their potential influence on behavior, highlighting their relevance in forensic toxicology and drug studies.
Abstract
Abstract not available from OpenAlex